• 응용통계연구
• /
• 제31권5호
• /
• pp.587-597
• /
• 2018

조사목적에 부합하는 표본 자료를 얻기 위해서는 추출방법 및 조사방법 결정, 설문지 작성 등의 절차가 필요하며 중요한 결정 중 하나가 표본크기 공식의 적용이다. 표본크기 공식은 추출방법에 따른 목표오차와 총비용 등을 설정함으로써 결정되는데 본 논문에서는 단순임의추출에서 목표오차와 예상 응답률이 주어져 있을 때 과거 및 현재 시점의 모집단의 변동과 과거 자료의 추정오차 및 응답률을 사용한 표본크기 공식을 제안한다. 실제조사에서는 설계가중치 외에도 여러 가중치가 복합적으로 적용되는 추정량을 사용하고 있는데 본 논문에서는 설계가중치와 무응답 보정계수를 사용한 추정량에서의 표본크기 공식을 유도하며 이것은 시점별 조사방법이 달라질 경우 응답률에 차이가 발생하는 현상을 반영한 공식이 될 수 있다. 또한 모의 실험을 통하여 기존의 표본크기 공식과 비교함으로써 제안된 공식의 다양한 적용방안을 살펴본다.

• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• 제25권6호
• /
• pp.461-472
• /
• 2022

Purpose: Golimumab (GLM) is an anti-tumor necrosis factor (TNF)-α antibody preparation known to be less immunogenic than infliximab (IFX) or adalimumab. Few reports on GLM in pediatric patients with ulcerative colitis (UC) are available. This study aimed to review the long-term durability and safety of GLM in a pediatric center. Methods: The medical records of 17 pediatric patients (eight boys and nine girls) who received GLM at the National Center for Child Health and Development were retrospectively reviewed. Results: The median age at GLM initiation was 13.9 (interquartile range 12.0-16.3) years. Fourteen patients had pancolitis, and 11 had severe disease (pediatric ulcerative colitis activity index ≥65). Ten patients were biologic-naive, and 50% achieved corticosteroid-free remission at week 54. Two patients discontinued prior anti-TNF-α agents because of adverse events during remission. Both showed responses to GLM without unfavorable events through week 54. However, the efficacy of GLM in patients who showed primary nonresponse or loss of response to IFX was limited. Four of the five patients showed non-response at week 54. Patients with severe disease had significantly lower corticosteroid-free remission rate at week 54 than those without severe disease. No severe adverse events were observed during the study period. Conclusion: GLM appears to be safe and useful for pediatric patients with UC. Patients with mild to moderate disease who responded to but had some adverse events with prior biologics may be good candidates for GLM. Its safety and low immunogenicity profile serve as favorable options for selected children with UC.